SAN FRANCISCO, Calif., March 5, 2014 – As a next step in a series
of corporate governance modifications, McKesson Corporation (NYSE: MCK) today
announced that its Board of Directors has elected N. Anthony Coles, M.D., as a
new independent director, effective April 29, 2014. In connection with Dr. Coles’ election, the size
of the Board of Directors was increased from nine to ten members, nine of whom
are independent.
“With over 20 years of experience in the
biopharmaceuticals and pharmaceutical industries, including several public
company leadership positions, Tony will provide unique perspectives that will
further diversify the expertise of our Board,” said John H. Hammergren,
chairman and chief executive officer, McKesson Corporation. “We are committed to maintaining the best
possible leadership team to continue guiding our strong financial performance. The addition of Tony to our Board represents
a continuation of initiatives already under way to address shareholder feedback
and maintain industry-leading governance practices.”
The Board has appointed Dr. Coles as a member of
its Compensation Committee and its Finance Committee. Dr. Coles’ term as a director will expire at
the Company’s 2014 Annual Meeting of Stockholders unless he is renominated as a
director, and elected by stockholders at the annual meeting in accordance with
McKesson’s majority voting standard.
N. Anthony
Coles, M.D.
Dr. Coles, 53, was President, Chief Executive
Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a
biopharmaceutical company, from 2012 until 2013, having served as its President
and Chief Executive Officer, and a member of its board of directors, from 2008
until 2012. From 2005 to 2008, Dr. Coles
served as an executive and a director of NPS Pharmaceuticals, Inc., a public
biopharmaceutical company (“NPS”). Dr.
Coles began his tenure at NPS as President and Chief Operating Officer and
ended his tenure there as President and Chief Executive Officer. Prior to 2005, Dr. Coles served in various leadership
positions in the biopharmaceutical and pharmaceutical industries, including at
Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex Pharmaceuticals
Incorporated.
About
McKesson Corporation
McKesson Corporation, currently ranked 14th on the
FORTUNE 500, is a healthcare services and information technology company
dedicated to making the business of healthcare run better. McKesson partners with payers, hospitals,
physician offices, pharmacies, pharmaceutical companies and others across the
spectrum of care to build healthier organizations that deliver better care to
patients in every setting. McKesson
helps its customers improve their financial, operational, and clinical
performance with solutions that include pharmaceutical and medical-surgical
supply management, healthcare information technology, and business and clinical
services. For more information, visit www.McKesson.com.
PR Contact
Contact Public Relations